Get the Stockscreener App
5.595
4.92%
-0.305
Phathom Pharmaceuticals Inc stock is traded at $5.595, with a volume of 544.57K.
It is down -4.92% in the last 24 hours and down -22.08% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$5.90
Open:
$5.9
24h Volume:
544.57K
Relative Volume:
0.43
Market Cap:
$403.43M
Revenue:
-
Net Income/Loss:
$-297.11M
P/E Ratio:
-1.078
EPS:
-5.19
Net Cash Flow:
$-216.95M
1W Performance:
-6.34%
1M Performance:
-22.08%
6M Performance:
-48.10%
1Y Performance:
-22.41%
1-Day Range:
$5.512
$5.92
1-Week Range:
$5.42
$6.3991
52-Week Range:
$5.42
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
5.59 | 403.43M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.76 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.15 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.44 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Phathom Pharmaceuticals Inc (PHAT) Stock: Assessing the Risk and Reward - The News Heater
The Future of Phathom Pharmaceuticals Inc: Analyzing PHAT - The InvestChronicle
Jennison Associates LLC Has $57.35 Million Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals Inc [PHAT] CFO and CBO makes an insider sale of 6,583 shares worth $43371.0. - Knox Daily
Closing Strong: Phathom Pharmaceuticals Inc (PHAT) Ends at 5.63, Down -6.01 from Last Close - The Dwinnex
A stock that deserves closer examination: Phathom Pharmaceuticals Inc (PHAT) - US Post News
Further weakness as Phathom Pharmaceuticals (NASDAQ:PHAT) drops 12% this week, taking five-year losses to 81% - Simply Wall St
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire Inc.
Exclusive: Phathom's Next-Gen GI Treatments Take Center Stage at Major Biotech Conference - StockTitan
Trading (PHAT) With Integrated Risk Controls - Stock Traders Daily
Phathom Pharmaceuticals CFO Molly Henderson sells shares worth $43,370 - MSN
Phathom Pharmaceuticals Stock: A Comprehensive Analysis of Recent Developments - The Digital Weekly
Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Sells 7,886 Shares of Stock - MarketBeat
Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 6,583 Shares of Stock - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 19,109 Shares - MarketBeat
Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Yahoo Finance
(PHAT) Technical Pivots with Risk Controls - Stock Traders Daily
Barclays PLC Buys 45,402 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World
Phathom Pharmaceuticals' (PHAT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
(PHAT) Proactive Strategies - Stock Traders Daily
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Sold by Jane Street Group LLC - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.9%Here's What Happened - MarketBeat
Barclays PLC Grows Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Geode Capital Management LLC Buys 56,871 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 7.1% HigherWhat's Next? - MarketBeat
State Street Corp Raises Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
State Street Corp Increases Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Phathom Pharmaceuticals CFO Molly Henderson sells $10,328 in stock By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals CFO Molly Henderson sells $10,328 in stock - Investing.com India
Phathom Pharmaceuticals COO sells shares for $8,944 - Investing.com India
Phathom Pharmaceuticals COO sells shares for $8,944 By Investing.com - Investing.com South Africa
Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 1,291 Shares of Stock - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 2%Here's Why - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) Recovers 28.94% From Low: Are We There Yet? - Stocks Register
Helicobacter pylori Infection Market to Show Remarkable Growth - openPR
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Insider Buying Activity - Defense World
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Frank Karbe buys $99,083 in Phathom Pharmaceuticals stock By Investing.com - Investing.com Australia
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nabulsi Azmi | Chief Operating Officer |
Jan 21 '25 |
Sale |
6.59 |
7,886 |
51,957 |
233,390 |
| Curran Terrie | President and Chief Executive |
Jan 21 '25 |
Sale |
6.59 |
19,109 |
125,884 |
360,465 |
| Nabulsi Azmi | Chief Operating Officer |
Dec 19 '24 |
Sale |
8.00 |
1,118 |
8,944 |
239,303 |
| Henderson Molly | CFO and CBO |
Dec 19 '24 |
Sale |
8.00 |
1,291 |
10,328 |
98,156 |
| KARBE FRANK | Director |
Dec 13 '24 |
Buy |
7.93 |
12,500 |
99,084 |
57,000 |
| Parikh Asit | Director |
Dec 13 '24 |
Buy |
8.12 |
10,000 |
81,248 |
75,500 |
| Nabulsi Azmi | Chief Operating Officer |
Jul 15 '24 |
Sale |
11.72 |
10,901 |
127,760 |
240,421 |
| Henderson Molly | CFO and CBO |
Jul 15 '24 |
Sale |
11.72 |
4,325 |
50,689 |
99,447 |
| Curran Terrie | President and Chief Executive |
Jul 15 '24 |
Sale |
11.72 |
33,848 |
396,699 |
377,734 |
| Henderson Molly | CFO and CBO |
Apr 08 '24 |
Sale |
11.10 |
3,435 |
38,128 |
95,263 |
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):